Bing

SEARCH HISTORY

This suggests that analysts have very recently bumped up their estimates for ARNA, giving the stock a Zacks Earnings ESP of 6.67% heading into earnings season. Why is this Important? A positive reading for the Zacks Earnings ESP has proven to be very ...
Yahoo Finance · 13 hours ago
Arena Pharmaceuticals (NASDAQ:ARNA) is scheduled to post its Q215 quarterly earnings ... on Arena Pharmaceuticals from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. One research analyst has rated …
sleekmoney.com · 11 hours ago
Arena Pharmaceuticals
In-depth coverage >
The stock has an average rating of “Hold” and an average target price of $6.45. Arena Pharmaceuticals (NASDAQ:ARNA) traded down 1.601% on Tuesday, reaching $3.995. 714,414 shares of the company traded hands. The stock’s market …
Ticker Report · 10 hours ago
Arena Pharmaceuticals
More from Bing News
Arena (NASDAQ:ARNA) investors have not had much to smile about in recent ... If a pipeline candidate can pass Phase 2 with success, we may then be able to see the stock appreciated by the street. The bottom line …
Seeking Alpha · BySpencer Osborne · 1 day ago
Belviq
Arena Pharmaceuticals (NASDAQ:ARNA) traded down 2.41% on Wednesday, hitting $4.05. The stock had a trading volume of 1,667,247 shares. Arena Pharmaceuticals has a 1-year low of $3.26 and a 1-year high of $6.28. The stock has a 50-day moving …
Mideast Times · 7/25/2015
Shares of Arena Pharmaceuticals (NASDAQ:ARNA) traded down 2.41% during mid-day trading on Wednesday, hitting $4.05. 1,667,247 shares of the company’s stock traded hands. Arena Pharmaceuticals has a one year low of $3.26 and a one year high …
wkrb13.com · 7/26/2015
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock has been on quite a roller coaster ride in 2015. A few weeks ago, ARNA shares roared 76% higher in a single day after positive early-stage trials for an autoimmune disease treatment gave investors a …
Investor Place · 1/22/2015
NEW YORK (TheStreet) -- Arena Pharmaceuticals (ARNA - Get Report) shares are down 1.63% to $4.29 in early market trading on Wednesday after the company announced that its CFO Robert E. Hoffman would be leaving the company on July 10.
The Street · 6/17/2015
NEW YORK, July 24, 2015 /PRNewswire via COMTEX/ -- NEW YORK, July 24, 2015 /PRNewswire/ -- Equity Research Institute has initiated coverage on the following equities: PDL BioPharma Inc. PDLI, -1.28% Arena Pharmaceuticals Inc. ARNA, -2.35% …
Market Watch · 7/24/2015
ARNA After Hours session closed @ 4.60, up another +1.21% on top of today's +2.36%. Added today to bring position up to 92% of my pre... Arena (ARNA) is a Winner For Investors Arena (ARNA) is a winner for investors ...and currently at a very attractive ...
Stockhouse · 7/29/2015